MMSI

Business Context and Reporting Period

Company: Merit Medical Systems, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Merit develops, manufactures, and markets disposable medical products primarily for diagnostic and interventional cardiology and radiology procedures. The company operates as a single segment with manufacturing facilities in the U.S., Ireland, and the Netherlands, and sales operations globally.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 9% driven by volume growth in custom kits/procedure trays (+11%) and catheters (+20%), partially offset by slight pricing declines in the market.
• Margin Expansion: Gross margin improved by 270 basis points to 41.1%. This was attributed to lower fixed overhead unit costs due to increased production, lower unit costs for products manufactured in Mexico, price increases, and production automation.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 10% to $53.1 million, primarily due to higher commissions, bonuses, and travel expenses. This included approximately $415,000 in net damages from Hurricane Ike affecting the Angleton, Texas facility.
• Tax Rate: The effective income tax rate increased to 35% from 33% in 2007, largely due to non-deductible investment losses in the deferred compensation plan.
• Cash Flow: Operating cash flow decreased by $4.0 million compared to 2007, primarily due to a $9.1 million increase in inventory levels.

Guidance, Outlook, and Risks

Outlook and Strategy: Management plans to implement automation and manufacturing cost-saving improvements in 2009. The company intends to identify a location outside the U.S. for a new manufacturing site to reduce product costs. Growth is expected to be driven by organic product introductions and acquisitions.

Recent Acquisitions (Subsequent Events):

• Alveolus, Inc.: Agreed to acquire assets for approximately $19.0 million (non-vascular interventional stents).
• Biosearch Medical Products: Agreed to acquire two gastroenterology products for approximately $1.6 million.

Key Risks and Contingencies:

• Acquisition Integration: Risks associated with closing and integrating the Alveolus and Biosearch transactions.
• Concentration: Inflation devices accounted for approximately 27% of total revenues; the single largest customer (an OEM partner) accounted for 7% of total sales.
• Regulatory: Dependence on FDA and foreign regulatory approvals; potential for product recalls or liability claims.
• Foreign Currency: Approximately 11% of sales were denominated in Euros and GBP; fluctuations could negatively impact margins.
• Supply Chain: Reliance on third-party sterilization and suppliers; potential disruption from natural disasters (e.g., Hurricane Ike impact in 2008).

Investor Verification Checklist

• Inventory Levels: Verify the rationale for the $4.0 million increase in inventory and the adequacy of the $2.3 million obsolescence reserve.
• Acquisition Synergies: Assess the integration plans and financial impact of the pending Alveolus ($19M) and Biosearch ($1.6M) acquisitions.
• Customer Concentration: Monitor the stability of the top OEM customer representing 7% of sales and the 27% revenue reliance on inflation devices.
• Foreign Exchange Exposure: Evaluate hedging strategies given the 11% exposure to Euro/GBP fluctuations.
• Capital Expenditures: Review the $14.5 million in capital expenditures for property and equipment to ensure alignment with capacity expansion plans.